Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026

All NewsAugust 20, 2025

William Blair starts Kyverna coverage with Outperform, citing KYV-101’s potential as the first FDA-approved CAR-T therapy in autoimmune disease.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent